-
Mashup Score: 0Addition of gemtuzumab ozogamicin to induction chemotherapy - 8 month(s) ago
We summarize several presentations from ASH 2022 on the impact of gemtuzumab ozogamicin plus chemotherapy and fractionated versus single dose schedule on survival outcomes in AML.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Developing targeted therapies to address heterogeneity in AML - 8 month(s) ago
Amir Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, comments on the heterogeneity of acute myeloid leukemia (AML) and how this impacts treatment approaches for patients. Dr Fathi explains that AML can involve different mutations and pathways across patients, but the primary treatment strategy remains to be intensive chemotherapy. Dr Fathi therefore notes that targeted therapies are currently being developed which could be combined with traditional treatments to reduce toxicity while maintaining high efficacy. To conclude, Dr Fathi highlights an ongoing Phase II multicenter study (NCT04801797) comparing intensive chemotherapy with the non-intensive azacitidine/venetoclax combination regimen in patients with AML. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reser
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Nature – Epitope engineering of donor haematopoietic stem/progenitor cells endows haematopoietic lineages with selective resistance to CAR T cells or monoclonal antibodies, without affecting…
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Bexmarilimab granted orphan drug designation by the U.S. FDA - 9 month(s) ago
On August 29, 2023, the U.S. FDA granted orphan drug designation to bexmarilimab, a first-in-class humanized monoclonal antibody, for the treatment of patients with AML.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Acute Myeloid Leukemia - VJHemOnc - 9 month(s) ago
Explore the latest Acute Myeloid Leukemia updates and expert interviews on The AML Channel from VJHemOnc
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Acute Myeloid Leukemia - VJHemOnc - 9 month(s) ago
Explore the latest Acute Myeloid Leukemia updates and expert interviews on The AML Channel from VJHemOnc
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate from next-generation ADC platform and its second IND clearance within 8 months, highlighting Vincerx’s development and regulatory expertise PALO ALTO, Calif. , Aug. 22, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc.
Source: investors.vincerx.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Alexander Edward Perl, MD- FLT3 and Therapeutic Resistance - 9 month(s) ago
Alexander Edward Perl, MD, MS – Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania Alexander Edward Per, MD, MS emphasizes the need to unravel the intricacies of both primary and secondary resistance mechanisms associated with FLT3 inhibitors, highlighting th…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Current and emerging treatment strategies for post-MPN AML - 9 month(s) ago
Pankit Vachhani, MD, University of Alabama at Birmingham, Birmingham, AL, discusses the biology and treatment of acute myeloid leukemia (AML) arising from a previous myeloproliferative neoplasm (MPN). Current treatments usually require intensive chemotherapy or hypomethylating agents (HMAs). Dr Vachhani discusses the potential of allogeneic stem cell transplantation (alloSCT) and provides insight into novel disease-modifying drugs under investigation for the treatment of these patients. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjhemonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 12seventy bio Reports Second Quarter Financial Results and Recent Operational Progress | 2seventy bio - 9 month(s) ago
Abecma (idecabtagene vicleucel) generated $115 million U.S. commercial revenue in 2Q 2023, supporting lower end of U.S. revenue guidance of $470-570 million 2seventy bio provides update on PLAT-08 study in AML with partner Seattle Children’s Ended quarter with $307 million cash, cash equivalents,
Source: ir.2seventybio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
In case you missed it: Does the addition of gemtuzumab ozogamicin to chemotherapy improve survival outcomes in patients with AML? Is a fractionated dosing schedule more effective than a single dose? Find out here 👉 https://t.co/9RtOQNUGam. #AMLsm #leusm https://t.co/ODizxP6H6v